[1]刘育苗,杨晓强△.脂必泰联合阿托伐他汀钙对冠心病患者血脂的影响[J].西部中医药,2018,31(12):89-91.
　LIU Yumiao,YANG Xiaoqiang.The Effects of ZhiBiTai Capsules and Atorvastatin Calcium on Blood Lipid of CHD Patients[J].Western Journal of Traditional Chinese Medicine,2018,31(12):89-91.
点击复制

脂必泰联合阿托伐他汀钙对冠心病患者血脂的影响
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
31
期数:
2018年12期
页码:
89-91
栏目:
出版日期:
2018-12-15

文章信息/Info

Title:
The Effects of ZhiBiTai Capsules and Atorvastatin Calcium on Blood Lipid of CHD Patients
文章编号:
1004-6852(2018)12-0089-03
作者:
刘育苗，杨晓强△
杨凌示范区医院，陕西 杨凌 712100
Author(s):
LIU Yumiao, YANG Xiaoqiang△
Yangling Demonstration Zone Hospital, Yangling 712100, China
关键词:
高脂血症; 冠心病; 脂必泰; 阿托伐他汀钙; 心肌营养因子1; 高敏C反应蛋白
Keywords:
hyperlipoidemia;  coronary heart disease;  ZhiBiTai;  atorvastatin calcium;  CT-1;  hs-CRP
分类号:
R541.4
摘要:
目的：观察脂必泰联合阿托伐他汀钙对冠心病(CHD)患者血脂的影响。方法：将120例患者随机分为3组，每组40例：ZA-10组以脂必泰480 mg+阿托伐他汀钙10 mg治疗；A-20组以阿托伐他汀钙20 mg治疗；A-40组以阿托伐他汀钙40 mg治疗，3组均治疗8周。测量患者治疗前后总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)及载脂蛋白ApoA1、ApoB100、心肌营养因子1(CT-1)、高敏C-反应蛋白(hs-CRP)、肌酸激酶同工酶(CK-MB)水平，观察不良反应发生情况。结果：治疗后TC、TG、LDL、ApoB100水平3组均显著下降(P＜0.05)；TG、LDL、ApoB100水平ZA-10组显著低于A-20、A-40组(P＜0.05)；3组患者载脂蛋白ApoA1水平比较无明显差异(P＞0.05)。血清CT-1和hs-CRP水平3组均显著下降(P＜0.05)；CK-MB水平下降不明显(P＞0.05)，hs-CRP水平ZA-10组与A-20、A-40组比较差异显著(P＜0.05)。不良反应发生率ZA-10组为17.5%，A-20组为25.0%，A-40组为30.0%，ZA-10组与A-40组比较，差异有统计学意义(P＜0.05)。结论：脂必泰和阿托伐他汀钙联用可显著降低冠心病患者的TC、TG、LDL、ApoB100、hs-CRP水平，可减少阿托伐他汀钙的用量，且不良反应较少。
Abstract:
Objective：To observe the effects of ZhiBiTai and atorvastatin calcium on blood lipid of the patients with coronary heart disease (CHD). Methods: All 120 patients were randomized into three groups, 40 cases each group: ZA-10 group were treated by ZhiBiTai capsules, 480mg and atorvastatin calcium, 10mg; A-20 group were given atorvastatin calcium, 20mg; A-40 group atorvastatin calcium, 40mg, three groups were treated for eight weeks. The levels of TC, TG, HDL and LDL ApoA1, ApoB100, cardiotrophin-1 (CT-1), high sensitivity C-reactive protein (hs-CRP) and CK-MB of the patients were detected before and after treating, the incidence of adverse reaction was observed. Results: After treating, the levels of TC, TG, LDL, ApoB100 of three groups lowered notably (P＜0.05); ZA-10 group was lower than A-20 and A-40 groups notably in the levels of TG, LDL and ApoB100 (P＜0.05); the obvious difference didn't existed in the comparison of the level of ApoA1 among three groups (P＞0.05). The levels of CT-1 and hs-CRP of three groups decreased remarkably (P＜0.05); the level of CK-MB decreased insignificantly (P＞0.05), the difference was significant in the comparison of the levels of hs-CRP when ZA-10 group was compared with A-20 and A-40 groups (P＜0.05). The incidences of adverse reaction of ZA-10 group, A-20 and A4- group were 17.5%, 25.0% and 30.0%, the difference had statistical meaning when ZA-10 group was compared with A-40 group (P＜0.05). Conclusion: The combination of ZhiBiTai capsules and atorvastatin calcium could decrease the levels of TC, TG, LDL, ApoB100 and hs-CRP with minor adverse reaction, and reduce the dose of atorvastatin calcium.

相似文献/References:

[1]马思清 指导：谢春毅.瓜蒌薤白三方防治冠心病的研究现状[J].西部中医药,2012,25(10):118.
　MA Si-qing Director: XIE Chun-yi.Exploration on Three Pieces of GuaLou XieBaiFang in the Prevention of Coronary Heart Disease[J].Western Journal of Traditional Chinese Medicine,2012,25(12):118.
[2]马乔娟.银杏叶提取物对绝经后冠心病妇女冠脉血流及血管弹性的影响[J].西部中医药,2013,26(02):24.
　MA Qiaojuan.Effects of Ginaton on Coronary Blood Flow and Vascular Elasticity of Postmenopausal Women with Coronary Heart Disease[J].Western Journal of Traditional Chinese Medicine,2013,26(12):24.
[3]王龙,王化良.王化良主任巧用经方治疗冠心病合并焦虑状态经验浅析[J].西部中医药,2013,26(03):39.
　WANG Long,WANG Hualiang.Analysis on Director WA NG Hualiang's Experience of Applying Classic Prescriptions to Coronary Heart Disease Complicated to Anxiety[J].Western Journal of Traditional Chinese Medicine,2013,26(12):39.
[4]滕云.七味消脂饮治疗高脂血症临床观察[J].西部中医药,2013,26(05):77.
　TENG Yun.Clinical Observation on QiWei XiaoZhiYin in Treating Hyperlipoidemia[J].Western Journal of Traditional Chinese Medicine,2013,26(12):77.
[5]高世东.从肝脾肾论治高脂血症[J].西部中医药,2013,26(06):18.
　GAO Shidong.On Hyperlipoidemia Treated from Liver, Spleen and Kidney[J].Western Journal of Traditional Chinese Medicine,2013,26(12):18.
[6]杨健,张红武△,杨如意.活血化浊胶囊治疗高脂血症的实验研究[J].西部中医药,2012,25(08):17.
　YANG Jian,ZHANG Hong-wu,YANG Ru-yi.Experimental Study on HuoXue HuaZhuo Capsule in Treating Hyperlipidemia[J].Western Journal of Traditional Chinese Medicine,2012,25(12):17.
[7]马丽.冠心病二级预防用药出院带药情况分析[J].西部中医药,2013,26(07):58.
　MA Li.Analysis on Prescribed Medications for Discharged Patients in Secondary Prevention of Coronary Heart Disease[J].Western Journal of Traditional Chinese Medicine,2013,26(12):58.
[8]潘雪晖.综合护理干预对冠心病患者不良生活方式的影响[J].西部中医药,2013,26(07):105.
　PAN Xuehui.Impact of Comprehensive Nursing Intervention on Lifestyles of Patients with Coronary Heart Disease[J].Western Journal of Traditional Chinese Medicine,2013,26(12):105.
[9]袁春玲.家庭病床冠心病护理可行性探讨[J].西部中医药,2012,25(07):109.
　YUAN Chun-ling.Probe into Feasibility of Nursing for Patients with Coronary Heart Disease in Family Practice[J].Western Journal of Traditional Chinese Medicine,2012,25(12):109.
[10]王凯,林文.丹红与丹参酮ⅡA治疗冠心病心绞痛疗效比较[J].西部中医药,2013,26(08):88.
　WANG Kai,LIN Wen.Comparison between DanHong Injection and Tanshinone ⅡA in Treating Angina Pectoris of Patients with Coronary Heart Disease[J].Western Journal of Traditional Chinese Medicine,2013,26(12):88.

备注/Memo

备注/Memo:
收稿日期：2018-04-27 作者简介：刘育苗(1978—)，女，主治医师。研究方向：心血管疾病的治疗。 △通讯作者：杨晓强(1977—)，男，副主任医师。研究方向：心血管疾病的治疗。
更新日期/Last Update: 2018-12-15